Mitiperstat is under clinical development by AstraZeneca and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mitiperstat LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mitiperstat is under development for the treatment of pulmonary arterial hypertension, non-cirrhotic non-alcoholic steatohepatitis with fibrosis, diastolic heart failure with preserved ejection fraction (HFpEF) and heart failure with left ventricular ejection fraction. It is a small molecule administered through oral route as a coated tablet, solution and suspension. AZD-4831 acts by targeting myeloperoxidase (MPO). The drug candidate is a new molecular entity (NME).
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Mitiperstat’s drug-specific PTSR and LoA scores, buy the report here.